Company intelligence / Profile preview

Enalees

Évry-Courcouronnes / Genopole Biocluster, Île-de-France, Franceenalees.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Enalees has commercialized nearly 60 rapid molecular diagnostic tests for animal health under the Epona® and Asteria® brands. The company also developed a CE-IVD certified COVID‑19 test during the pandemic. Their technology enables pathogen detection within about 40 minutes at point-of-care without specialized lab equipment.

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnostic test (PCR & NAAT Nucleic Acid Amplification Tests)Isothermal amplification (LAMP)Lyophilized molecular diagnostic testDevice (portable reader for rapid diagnostics)
Industry: Molecular Diagnostics

Partnerships

Collaborations with French companies on COVID testing

Beyond the preview

Go deeper on Enalees.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enalees.

Explore the full profile